therapeutic strategies in adjuvant therapy of colon cancer
DESCRIPTION
Therapeutic Strategies in Adjuvant Therapy of Colon Cancer. Mohamed Abdulla (M.D.) Prof. of Clinical Oncology, Kasr El-Aini School of Medicine, Cairo University. 01/04/2010. Colon Cancer; Challenging Issues:. Better Understanding of the Molecular Events. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/1.jpg)
Therapeutic Strategies in Adjuvant Therapy of Colon Cancer
Mohamed Abdulla (M.D.)Prof. of Clinical Oncology,Kasr El-Aini School of Medicine,Cairo University.
01/04/2010
![Page 2: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/2.jpg)
Colon Cancer; Challenging Issues: Better Understanding of the Molecular
Events. Better Characterization of Prognostic
Groups. Diagnosis in Younger Age Groups with
Aggressive Behavior. Introduction of Pharmaceuticals Other
Than Fluoropyremidines. Introduction of Targeted Therapies.
![Page 3: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/3.jpg)
The Adenoma-Carcinoma Process:
Kinzler KW, et al. New York, The genetic basis of human cancer. NY: McGraw-Hill, 1998:565-87. Vogelstein B, et al. N Engl J Med. 1988;319:525-532. Fearon ER, et al. Cell. 1990;61:759-767.
Normal colonic epithelium
Dysplastic aberrant crypt foci
Initial adenoma develops
Intermediate adenoma
Late adenoma
Carcinoma
Metastasis
Mutation in APC
Mutation in K-ras
Mutation in DCC
Mutation in p53
Other alteration?
EGFR & VEGF
![Page 4: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/4.jpg)
Who Should Receive Adjuvant Therapy?1. Staging System:
Stage 0 month 30 m 60 m% Survival % Survival % Survival
I 100 96.1 93.2IIa 100 91.0 84.7IIb 100 80.2 72.2IIIa 100 91.4 83.4IIIb 100 77.3 64.1IIIc 100 67.1 52.3IIId 100 57.3 43.0IIIe 100 43.1 26.8IV 100 17.3 8.1
O’ConnellJB, Maggard MA, Ko CY: Colon Cancer Survival Rates with The New American Joint Committee on Cancer, Sixth Edition Staging. J Natl Cancer Inst 2004;96:1423.
LNs = > 12
![Page 5: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/5.jpg)
Who Should Receive Adjuvant Therapy?2. Mesentric Nodules: (Contour Role):
T-Stage N-Stage
1. V1 (micro).
2. V2 (macro)
Isolated Tumor Cells &
Micrometastases
0 – 0.2 mm (N0)
0.2 – 2 mm (N1mi)
Stage III Not IV
Cancer 2008;112:50–4.
![Page 6: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/6.jpg)
Who Should Receive Adjuvant Therapy?3. Peri-neural Invasion:An Under-Estimated Variable:
15 – 25%
JCO.2009.22.4949
![Page 7: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/7.jpg)
Who Should Receive Adjuvant Therapy?3. Peritoneal Minimal Residual Disease:
1/5 : Peritoneal Minimal Residual Disease.
1/7 : Peritoneal Carcinomatois.
Surgical Techniques. Intraperitoneal & Intraportal Chemotherapy. HIPEC. Prevention of The Inflammatory Response.
thelancet.com/oncology Vol 10 January 2009
![Page 8: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/8.jpg)
Who Should Receive Adjuvant Therapy?4. Age Factor:
Bouvier et al, CANCER August 15, 2008 / Volume 113 / Number 4
![Page 9: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/9.jpg)
Who Should Receive Adjuvant Therapy?5. Timing of Chemotherapy Initiation:
Hershman et al, CANCER December 1, 2006 / Volume 107 / Number 11
![Page 10: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/10.jpg)
![Page 11: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/11.jpg)
Accepted Standards of Care:Stage III Colon Cancer
Stage III Colon Cancer Patients
5-Fu/Leucovorin
Mayo Clinic Roswell Park De Gramont
Lower Toxicity Profile & Better
Compliance
NSABP Co1-6
IMPACT
NCCTG
NCIC-CTG 30%
![Page 12: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/12.jpg)
Chemotherapeutics Other Than Fluoropyremidines:Stage III Colon Cancer:
Oxaliplatin
UFT
Capecitabine
Irinotecan
Effectiveness.Comparable Toxicity Profiles
![Page 13: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/13.jpg)
Adjuvant FOLFOX4 in Stage II-III Colon Cancer: MOSAIC Study Schema
de Gramont A, et al. ASCO 2007. Abstract 4007.
FOLFOX4
Leucovorin 200 mg/m2 IV +5-FU 400 mg/m2 bolus +
5-FU 600 mg/m2 IV over 22 hrs +Oxaliplatin 85 mg/m2 IV
(n = 1123)
LV5FU2
Leucovorin 200 mg/m2 IV +5-FU 400 mg/m2 bolus +
5-FU 600 mg/m2 IV over 22 hrs(n = 1123)
Patients with previously untreated, completely resected
stage II-III colon cancer
(N = 2246)
![Page 14: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/14.jpg)
MOSAIC Study: 6-Y OAS; by Treatment Arm:
J Clin Oncol. 2009,27:3109-3116
![Page 15: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/15.jpg)
MOSAIC Study: 6-Y OAS; by Treatment Arm & Stage:
J Clin Oncol. 2009,27:3109-3116
![Page 16: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/16.jpg)
Final MOSAIC Results (cont’d)
Rate of peripheral sensory neuropathy decreased over time At 4 yrs
Grade 1: 12.0% Grade 2: 2.8% Grade 3: 0.7%
Neutropenia ≥ grade 3 in 41.0% of patients receiving FOLFOX4 vs 4.7% of patients receiving LV5FU2 Febrile neutropenia in 1.8% of patients receiving FOLFOX4
de Gramont A, et al. ASCO 2007. Abstract 4007.
![Page 17: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/17.jpg)
No Significant Survival Advantage for The Following Groups: Stage II Disease.
Stage III Disease:
1. Female Sex.
2. > 65 Years old.
3. T4 Tumors.
4. N1 Disease.
5. Poorly Differentiated Tumors.
6. CEA > 5.
7. Vascular Invasion.
Final MOSAIC Results (cont’d)
J Clin Oncol. 2009,27:3109-3116J Clin Oncol, Vol 27, No 19 (July 1), 2009: pp 3082-3084
![Page 18: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/18.jpg)
Role of Irinotecan in Adjuvant Treatment of Stage III Colon Cancer PETACC-3 Study:
J Clin Oncol.2009,27:3117-3125
![Page 19: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/19.jpg)
Role of Irinotecan in Adjuvant Treatment of Stage III Colon Cancer PETACC-3 Study:
J Clin Oncol.2009,27:3117-3125
![Page 20: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/20.jpg)
Role of Irinotecan in Adjuvant Treatment of Stage III Colon Cancer PETACC-3 Study:
J Clin Oncol.2009,27:3117-3125
After Exclusion of Cases Developed Second Primary in Both Arms
![Page 21: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/21.jpg)
Oxaliplatin Versus Irinotecan:
Equivalent PFS in Head to Head Comparison in Metastatic Sitting.
Biological Alteration in Metastatic or Recurrent Disease (Topoisomerase I).
J Clin Oncol.2005, 23:4866-4875
![Page 22: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/22.jpg)
IntestineLiver
Capecitabine
5'-DFCR
5'-DFUR
CyD
5'-DFCR
5'-DFUR
5-FU
Tumor >> healthy tissueCapecitabine
CyD
CE
5'-DFCR = 5'-deoxy-5-fluorocytidine; 5'-DFUR = 5'-deoxy-5-fluorouridine;CyD = cytidine deaminase; CE = carboxylesterase
Capecitabine mode of action:TP-activation – proof of concept at last?
Thymidinephosphorylase (TP)
![Page 23: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/23.jpg)
X-ACT: Xeloda (capecitabine) Adjuvant Chemotherapy Trial of stage III colon cancer
Primary endpoint: non-inferiority in DFS Secondary endpoint: OS
Bolus 5-FU/LV5-FU 425mg/m2 +
LV 20mg/m2 days 1–5 q4w
Capecitabine1,250mg/m2 b.i.d. days 1–14 q3w
Chemonaïve stage IIIresection 8 weeks
n=1, 004
n=983
RANDO MISATION
Data cut-off: January 2007b.i.d. = twice daily
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
![Page 24: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/24.jpg)
X-ACT: Xeloda (capecitabine) Adjuvant Chemotherapy Trial of stage III colon cancer
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
5-year DFS (%)Capecitabine 1, 004 60.85-FU/LV 983 56.7
1.0
0.8
0.6
0.4
0.2
0
0 6 42 48 78 96
Months
HR=0.88 (95% CI: 0.77–1.01)NI margin 1.20
12 18 24 30 36 54 60 66 72 84 90
ITT population
Estim
ated
pro
babi
lity
102
n
Test of non-inferiority p<0.0001Test of superiority p=0.0682
![Page 25: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/25.jpg)
X-ACT: 5-year OS (median follow-up 6.8 years)
HR=0.86 (95% CI: 0.74–1.01)NI margin 1.14
0 6 42 48 78 9612 18 24 30 36 54 60 66 72 84 90 102
1.0
0.8
0.6
0.4
0.2
0
Estim
ated
pro
babi
lity
Test of non-inferiority p=0.000116Test of superiority p=0.06
5-year OS (%)Capecitabine 1, 004 71.45-FU/LV 983 68.4
n
0 6 42 48 78 96
Months
12 18 24 30 36 54 60 66 72 84 90 102
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
![Page 26: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/26.jpg)
Neutropenia
Nausea/
vomiting
Stomatitis
Diarrhoea
Febrile
neutropenia HFS
Patie
nts
(%)
* * * *
*p<0.001HFS = hand foot syndrome
Capecitabine (n=993) 5-FU/LV (n=974)
Grade 3/4 adverse events50
40
30
20
10
0
X-ACT: 5-year OS (median follow-up 6.8 years)
Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)
![Page 27: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/27.jpg)
X-ACT and MOSAIC: projection of OS in stage III patients
ITT population
Estim
ated
pro
babi
lity
0 2 4 6 8
1.0
0.8
0.6
0.4
Years
X-ACT1
Bolus 5-FU/LV (n=983)
Capecitabine (n=1,004)
MOSAIC2
LV5FU2 (n=675)
FOLFOX (n=672)
1Twelves C, et al. Eur J Cancer Suppl 2007;5:1 (Abstract 1LB)2De Gramont A, et al. J Clin Oncol 2007;25:(Suppl. 18):165s (Abstract 4007)
Estim
ated
pro
babi
lity
1.0
0.8
0.6
0.4
Years0 2 4 6 8
![Page 28: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/28.jpg)
Chemo/radiotherapy-naïve stage III colon cancer
Bolus 5-FU/LVMayo Clinic or Roswell Park
CAPOXCapecitabine 1,000mg/m2 b.i.d. days 1–15 Oxaliplatin 130mg/m2 day 1 q3w
Schmoll HJ, et al. J Clin Oncol 2007;25:4217–23
CAPOX: a new optionin the adjuvant setting:
Primary endpoint: disease-free survival
n=944
n=942
RANDO MISATION
![Page 29: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/29.jpg)
Grade 3/4 adverse events
Patie
nts
(%)
CAPOX1 (n=938) FOLFOX42 (n=1,108)FLOX3 (n=1,200)
Cross-trial comparison*Not reported
Neutropenia
Nausea
Stomatitis
Diarrhoea
Febrile
neutropenia HFS
Vomiting
Neurosensory
1Schmiegel WH, et al. J Clin Oncol 2007;25(Suppl. 18):172s (Abstract 4034)2André T, et al. N Engl J Med 2004;350:2343–51
3Wolmark N, et al. J Clin Oncol 2005;23(Suppl. 16 Pt I):246s (Abstract LBA 3500)
*
Adjuvant CAPOX: favourable toxicity compared with FOLFOX and FLOX:
* *
50
40
30
20
10
0
![Page 30: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/30.jpg)
Newly Emerged Strategies:Stage III Colon Cancer:NSABP-C0 - 6: 1608 pts
UFT 5-Fu/LV
DFS
OAS
66.9% 68.3%
78.7% 78.7%
Similar Toxicity Profile
![Page 31: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/31.jpg)
Targeted Therapy in The Adjuvant Sitting
EGFR
HER2
HER3
HER4
![Page 32: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/32.jpg)
Stages at which angiogenesis plays a role in tumor progression
Premalignantstage
Malignanttumor
Tumorgrowth
Vascularinvasion
Dormantmicrometastasis
Overtmetastasis
Avasculartumor
Angiogenicswitch
Vascularizedtumor
Tumor cellintravasation
Seeding indistant organs
Secondaryangiogenesis
Angiogenesis Is Involved Throughout Tumor Growth and Metastasis
Poon RT, et al. J Clin Oncol. 2001;19:1207-1225. Reproduced with permission from the American Society of Clinical Oncology.
![Page 33: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/33.jpg)
Trials of bevacizumab/capecitabine/Oxaliplatin in the adjuvant setting
Trial n Cancer Treatment
E5202 (Cooperative)
3,610 Stage II colon FOLFOX ± bevacizumab (high risk) Observation (low risk)
NSABP C-08 (Cooperative)
2,714 Stage II/III colon FOLFOX ± bevacizumab
QUASAR-2 (Cooperative)
2,240 Stage II/III colon Capecitabine ± bevacizumab
XELOXA (Cooperative)
1,886 Stage III colon CAPOX vs bolus 5-FU (Mayo Clinic or Roswell Park regimen)
AVANT (Roche)
3,450 Stage II/III colon FOLFOX vs FOLFOX + bevacizumab vs XELOX + bevacizumab
![Page 34: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/34.jpg)
Important adjuvant capecitabine/bevacizumab-based combination trials
2004 2005 2006 2007 2008 2009 2010 2011
XELOXA final safety
XELOXA 1° efficacy
XELOXA survival follow-up
QUASAR-2 1° efficacy
AVANT 1° efficacy
NSABP C-08 1° efficacy
![Page 35: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/35.jpg)
NSABP Protocol C-08: mFOLFOX ± Bevacizumab in Stage II/III CRC
Wolmark N, et al. ASCO 2009. Abstract LBA4.
Arm A: mFOLFOX6 Q2W x 26 (n = 1356)
Arm B: mFOLFOX6 + Bevacizumab 5 mg/kg Q2W x 26
(n = 1354)
Pts with stage II or III colon adenocarcinoma with ECOG PS of 0/11
(N = 2710)
Pts stratified by number of positive lymph nodes and randomized between Days 29 and 50 postoperatively
mFOLFOX6 regimen: LV 400 mg/m2 IV, 5-FU 400 mg/m2 IV, 5-FU 2400 mg/m2 over 46 hours; oxaliplatin 85 mg/m2 IV
Primary endpoint: DFS
![Page 36: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/36.jpg)
NSABP Protocol C-08: 3-Yr DFS Results:
Wolmark N, et al. ASCO 2009. Abstract LBA4.
DFS
(%)
Yrs
0
20
40
60
80
100
0 0.5 1.0 1.5 2.0 2.5 3.0 3.5
HR: 0.89 (P = .15)mFF6 + BmFF6
Events291312
3-Yr DFS77.475.5
![Page 37: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/37.jpg)
Anti-EGFR in Adjuvant ttt of Stage III Colon Cancer:
Study Duration: 11/05 11/11. DFS, OAS & Safety. FOLFOX4+Cetuximab vs FOLFOX4. ??
![Page 38: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/38.jpg)
Stage II Disease:
Stage II Stage IIIStage II Stage IIIStage IIStage II Stage IIIStage II
Stage II Stage III
![Page 39: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/39.jpg)
Issues to Be Considered:
75 – 80% are cured with surgery alone. No current method to identify the subset
of patients at higher risk of recurrence. Minimal benefit of adding chemotherapy. The associated significant morbidity.
![Page 40: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/40.jpg)
Stage II Colon Cancer:
QUASAR STUDY, 20043300 PTSSurgery Surgery +
5-Fu/LV
5% OAS
1% Mortality
5% OAS5% OAS
1% Mortality
5% OAS
![Page 41: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/41.jpg)
Stage II Colon Cancer:NSABP
C 01, 02, 04, 06(1851 Pts)
5 Reference
Genes
7Recurrence
Genes
6Treatment Benefit
Genes
QUASAR Study(1436/3239 Pts)
Surgery Surgery + 5-Fu/LV
Kerr D, et al. ASCO 2009. Abstract 4000.
![Page 42: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/42.jpg)
Clinical or Pathologic Variable HR (95% CI) P ValueMMR (deficient vs proficient) 0.32 (0.15-0.69) < .001
Tumor stage (T4 vs T3) 1.83 (1.23-2.75) .005
Tumor grade (high vs low) 0.62 (0.40-0.96) .026
Number of nodes examined (< vs ≥ 12) 1.47 (1.01-2.14) .040
LVI (present vs absent) 1.40 (0.88-2.23) .175
Recurrence score (continuous, per 25 units) 1.61 (1.13-2.29) .008
Stage II Colon Cancer:QUASAR Validation Results:
• Recurrence score (per 25 units) predictive of DFS and OS DFS HR: 1.42 (95% CI: 1.09-1.84; P = .010) OS HR: 1.33 (95% CI: 1.01-1.76; P = .041)• No significant differences in treatment score by treatment interaction in OS, DFS, or relapse-free interval
Kerr D, et al. ASCO 2009. Abstract 4000.
![Page 43: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/43.jpg)
Prognostic Value of CRC Biomarkers: Translational Study on PETACC 3
Roth AD, et al. ASCO 2009. Abstract 4002.
Study designed to compare the incidence of molecular biomarkers in pts with stage II/III CRC in the PETACC 3 trial (N = 3278).
Frequency of MSI-H significantly higher in stage II (22%) vs stage III (12%) disease (P < .0001).
Higher frequency of MSI detected in N0 tumors compared with N1 or N2 (P < .0001).
Higher tumor stage correlated with increased frequency of MSI (T1/T2 vs T3 vs T4) (P = .037).
![Page 44: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/44.jpg)
Translational Study on PETACC 3: Results:
Strong effect in stage II, decreases in stage III disease
Parameter, % HR 95% CI P ValueBoth stage II and III (N = 1233) RFS 0.569 0.400-0.811 .0018 OS 0.548 0.357-0.842 .006
Stage II (n = 391) RFS 0.265 0.107-0.661 .0044 OS 0.159 0.039-0.659 .011
Stage III (n = 842) RFS 0.693 0.473-1.02 .06 OS 0.699 0.446-1.09 .12
Roth AD, et al. ASCO 2009. Abstract 4002.
![Page 45: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/45.jpg)
Stage II Colon Cancer:Preoperative CEA Level:
Journal of Surgical Oncology 2009;99:65–70
![Page 46: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/46.jpg)
![Page 47: Therapeutic Strategies in Adjuvant Therapy of Colon Cancer](https://reader035.vdocuments.us/reader035/viewer/2022062301/56815e2a550346895dcc83c4/html5/thumbnails/47.jpg)
Keep in Mind:
Number of LNs > 12. Timing: 4-8 wks. Age. Molecular Markers. 5-Fu/LV is the Backbone. Stage II Disease: Better Assessment. Stage III Disease: MOSAIC & X-ACT. The Role of Adjuvant Targeted Therapy.